Intranasal Civamide for Episodic Cluster Headache

Episodic Cluster Headache Clinical Trial

Official title:
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache

Status Completed

Clinical Trial Summary

This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive substance which does not contain any active ingredients).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00069082
Study type	Interventional
Source	Winston Laboratories
Contact
Status	Completed
Phase	Phase 3
Start date	August 2003
Completion date	January 2004

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT01341548` - Civamide Nasal Solution for Cluster Headache	Phase 3
Terminated	`NCT02209155` - R-Verapamil for the Prophylaxis of Episodic Cluster Headache	Phase 2
Unknown status	`NCT00399243` - Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache	Phase 4
Completed	`NCT02397473` - A Study Of Galcanezumab In Participants With Episodic Cluster Headache	Phase 3
Completed	`NCT02797951` - A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache	Phase 3
Completed	`NCT00033839` - A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache	Phase 3
Terminated	`NCT02945046` - A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)	Phase 3